Analysis of Lyso-Globotriaosylsphingosine in Dried Blood Spots
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Recently, lyso-globotriaosylsphingosine (lyso-Gb3) was found to be elevated in plasma of treatment naive male patients and some female patients with Fabry Disease (FD). This study tested whether lyso-Gb3 could be analyzed in dried blood spots (DBS) from filter cards and whether concentrations are elevated in newborn infants with FD. Lyso-Gb3 concentrations were analyzed in DBS following extraction using a novel HPLC-mass spectrometry (MS)/MS method. Lyso-Gb3 levels in DBS were above the lower limit of quantitation (0.28 ng/mL) in 5/17 newborn FD infants (16 males; range: 1.02-8.81 ng/mL), but in none of the newborn controls, in all 13 patients (4 males) with classic FD (range: 2.06-54.1ng/mL), in 125/159 Taiwanese individuals with symptomatic or asymptomatic FD who carry the late onset α-galactosidase A (GLA) mutation c.936+919G>A (IVS4+919G>A) (3.75±0.69 ng/mL; range: 0.418-3.97 ng/mL) and in 20/29 healthy controls (0.77±0.24 ng/mL;range: 0.507-1.4 ng/mL). The HPLC-MS/MS method for analysis of lyso-Gb3 is robust and yields reproducible results in DBS in patients with FD. However, concentrations of lyso-Gb3 were below the limit of quantitation in most newborn infants with FD rendering this approach not suitable for newborn screening. In addition, most females with the late onset mutation have undetectable lyso-Gb3 concentrations.
Abstract
Recently, lyso-globotriaosylsphingosine (lyso-Gb3) was found to be elevated in plasma of treatment naive male patients and some female patients with Fabry Disease (FD). This study tested whether lyso-Gb3 could be analyzed in dried blood spots (DBS) from filter cards and whether concentrations are elevated in newborn infants with FD. Lyso-Gb3 concentrations were analyzed in DBS following extraction using a novel HPLC-mass spectrometry (MS)/MS method. Lyso-Gb3 levels in DBS were above the lower limit of quantitation (0.28 ng/mL) in 5/17 newborn FD infants (16 males; range: 1.02-8.81 ng/mL), but in none of the newborn controls, in all 13 patients (4 males) with classic FD (range: 2.06-54.1ng/mL), in 125/159 Taiwanese individuals with symptomatic or asymptomatic FD who carry the late onset α-galactosidase A (GLA) mutation c.936+919G>A (IVS4+919G>A) (3.75±0.69 ng/mL; range: 0.418-3.97 ng/mL) and in 20/29 healthy controls (0.77±0.24 ng/mL;range: 0.507-1.4 ng/mL). The HPLC-MS/MS method for analysis of lyso-Gb3 is robust and yields reproducible results in DBS in patients with FD. However, concentrations of lyso-Gb3 were below the limit of quantitation in most newborn infants with FD rendering this approach not suitable for newborn screening. In addition, most females with the late onset mutation have undetectable lyso-Gb3 concentrations.
참고문헌 (14)
- Zarate YA, "Fabry’s disease", Lancet, 372, pp.1427~1435 (2008)
- Gal A, "Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group", J Inherit Metab Dis, 34, pp.509~514 (2011)
- Dajnoki A, "Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry", Clin Chim Acta, 411, pp.1428~1431 (2010)
- MacDermot KD, "Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females", J Med Genet, 38, pp.769~775 (2001)
- Fauler G, "Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard", Rapid Commun Mass Spectrom, 19, pp.1499~1506 (2005)
- Paschke E, "Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study", Am J Kidney Dis, 57, pp.673~681 (2011)
- Rombach SM, "Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease", Biochim Biophys Acta, 1802, pp.741~748 (2010)
- Aerts JM, "Elevated globotriaosylsphingosine is a hallmark of Fabry disease", Proc Natl Acad Sci U S A, 105, pp.2812~2817 (2008)
- Kalliokoski RJ, "Structural and functional changes in peripheral vasculature of Fabry patients", J Inherit Metab Dis, 29, pp.660~666 (2006)
- Hwu WL, "Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)", Hum Mutat, 30, pp.1397~1405 (2009)
- Adam BW, "Recoveries of phenylalanine from two sets of dried-blood-spot reference materials: prediction from hematocrit, spot volume, and paper matrix", Clin Chem, 46, pp.126~128 (2000)
- Chace DH, "Validation of accuracy-based amino acid reference materials in dried-blood spots by tandem mass spectrometry for newborn screening assays", Clin Chem, 45, pp.1269~1277 (1999)
- van Breemen MJ, "Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy", Biochim Biophys Acta, 1812, pp.70~76 (2011)
- Togawa T, "Plasma globotriaosylsphingosine as a biomarker of Fabry disease", Mol Genet Metab, 100, pp.257~261 (2010)